Real-world characteristics and outcomes of <i>ERBB2-</i> mutant NSCLC in Latin American patients (CLICaP)
Bibliographic record
Abstract
INTRODUCTION: ERBB2-mutant non-small cell lung cancer (NSCLC) represents approximately 1%-4% of all lung adenocarcinomas (LUADs) and has emerged as a distinct molecular subtype. Little is known about NSCLC harboring ERBB2 mutations in Latin America. This study aimed to characterize the real-world clinical characteristics and outcomes of ERBB2-mutant NSCLC in Latin America. MATERIALS AND METHODS: Patients with NSCLC harboring ERBB2 mutations detected by next-generation sequencing in tumors or cfDNA were identified in databanks from 3 Latin American countries (Brazil, Colombia, and Mexico). Demographic, clinical, and pathological data were retrieved from electronic medical records. RESULTS: Of 1245 patients with NSCLC included from January 2015 to September 2022, 35 (2.8%) patients had tumors with ERBB2 mutations. The median age was 60 years (IQR: 49-69), 54.2% of patients were females, 59.4% were never smokers, 51.3% had baseline performance status ECOG 0, 91.5% were diagnosed with stage IV disease, and 29.7% had de novo brain metastasis. The most common ERBB2 mutations were A775_G776insYVMA (40%) and G780_P781dupGSP (20%). The most often co-mutated gene was TP53 (17.1%), and the median tumor mutation burden was 2 mut/Mb (IQR: 1-4). PD-L1 tumor proportion score was ≥50%, 1%-49%, and <1% in 11.4%, 54.2%, and 31.4%, respectively. Regarding treatment patterns, 74.2% of patients received chemotherapy (CT) plus immune checkpoint blockade (ICB) in the first line, and 42.8% received antibody-drug conjugates (ADC) targeting ERBB2 in further lines of therapy, especially trastuzumab emtansine (37.1%) and trastuzumab deruxtecan (5.7%). The median real-world progression-free survival (rwPFS) to the first line was 6.7 months (95%CI, 5.65-8.48). The median real-world overall survival (rwOS) for the entire cohort was 25.9 months (95% CI, 24.4-27.9). CONCLUSION: This study demonstrated that ERBB2-mutant NSCLC is uncommon among Latin American patients. Despite the vast majority of patients being treated with chemo-immunotherapy (ICB) in the first line, the median rwOS was similar to that reported for non-oncogene-addicted NSCLC.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".